Journal
PLACENTA
Volume 27, Issue 11-12, Pages 1060-1072Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.placenta.2005.11.009
Keywords
placenta; fetal membranes; cytokines; prostaglandins; protease; human pregnancy; NF-kappa B; PPAR-gamma; MAPK
Ask authors/readers for more resources
Phospholipid-derived mediators, inflammatory cytokines and extracellular matrix remodelling enzymes are all involved in the initiation of human tabour and delivery. We have previously demonstrated that natural and synthetic PPAR-gamma ligands regulate LPS-stimulated pro-inflammatory cytokine release from human gestational tissues, however, the effect of these ligands on the basal and/or LPS-induced expression of prostaglandins and proteases is not known. Therefore, the aim of this study was to determine the effects of 15d-PGJ(2) and troglitazone on the expression of basal and LPS-stimulated inflammatory mediators in human gestational tissues. Human placenta, amnion and choriodecidua (n = 5) were incubated in the presence or absence of 15 mu M 15d-PGJ(2) and 30 mu M troglitazone under basal and LPS-stimulated (10 mu g/ml) conditions. Treatment of placenta, amnion and choriodecidua, with both 15d-PGJ(2) and troglitazone decreased basal and LPS-stimulated IL-10, IL-6, IL- 10 and TNF-alpha release. Basal type II PLA(2) release from placental tissues was also significantly decreased by 15d-PGJ(2) and troglitazone. There was no effects of 15d-PGJ(2) and troglitazone on cPLA(2) protein expression. Both 15d-PGJ(2) and troglitazone significantly decreased basal and LPS-stimulated PGE(2) and PGF(2). release from placenta and amnion. However, in choriodecidua, although 15d-PGJ(2) decreased basal and/or LPS-stimulated PGE(2) and PGF(2), release, there was an increase in PGE(2) and PGF(2 alpha) release in the presence of troglitazone. 15d-PGJ(2) and troglitazone inhibited MMP-9 release from human amnion. NF-kappa B DNA binding activity and NF-kappa B p65 protein expression was inhibited by treatment with 15d-PGJ(2) in human amnion. There was no effect of 15d-PGJ(2) or troglitazone on PPAR-gamma protein, and GW9662 failed to alleviate 15d-PGJ(2) and troglitazone inhibition of IL-6 and TNF-a release in placenta, amnion and choriodecidua. The data demonstrated in this study suggest that the 15d-PGJ(2) and troglitazone exhibit anti-inflammatory properties in human gestational tissues via PPAR-gamma independent actions. (c) 2005 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available